TABLE 1.
Demographics and Clinical Characteristics of AI/AN Children < 5 y of Age Hospitalized With RSV-associated Acute Respiratory Infection by Site, November 2019 to May 2020
| Variablef | Chinle, Arizona N = 50 | Whiteriver, Arizona N = 32 | Anchorage, Alaska N = 20 | Yukon-Kuskokwim Delta, Alaska N = 69 |
|---|---|---|---|---|
| Male, n (%) | 28 (56.0) | 14 (43.8) | 10 (50.0) | 34 (49.3) |
| Age in months, mean (range) | 17.3 (0–54) | 14.9 (0–41) | 10.6 (1–54) | 9.8 (0–56) |
| Age group (months), n (%) | ||||
| 0 to <3 | 4 (8.0) | 2 (6.3) | 8 (40.0) | 15 (21.7) |
| 3 to <6 | 8 (16.0) | 4 (12.5) | 3 (15.0) | 14 (20.3) |
| 6 to <12 | 10 (20.0) | 9 (28.1) | 0 | 22 (31.9) |
| 12 to <24 | 15 (30.0) | 11 (34.4) | 8 (40.0) | 11 (15.9) |
| 24 to <36 | 7 (14.0) | 4 (12.5) | 0 | 5 (7.3) |
| 36 to <48 | 3 (6.0) | 2 (6.3) | 0 | 1 (1.5) |
| 48 to <60 | 3 (6.0) | 0 | 1 (5.0) | 1 (1.5) |
| Other children <5 y in home, n (%) | 48 (96.0) | 28 (87.5) | 19 (95.0) | 52 (75.4) |
| Currently breastfed (children <2 y)a, n (%) | 10 (27.0) | 5 (19.2) | 6 (31.6) | 23 (37.1) |
| Tobacco smoker in the home, n (%) | 2 (4.0) | 1 (3.1) | 9 (45.0) | 31 (44.9) |
| Running water in the home, n (%) | 41 (82.0) | 32 (100) | 18 (90.0) | 39 (56.5) |
| Any underlying conditionb, n (%) | 22 (45.8) | 10 (33.3) | 15 (79.0) | 46 (71.9) |
| History of prematurity (<37 wk) (children <2 y), n (%) | 3 (8.1) | 6 (23.1) | 5 (26.3) | 15 (24.2) |
| Any underlying condition or history of prematurity, n (%) | 23 (46.9) | 13 (40.6) | 16 (80.0) | 49 (73.1) |
| Received palivizumab (children <2 y)c, n (%) | 0 | 1 (3.9) | 0 | 3 (4.8) |
| Length of hospital stay (days), mean (range) | 3.5 (1–14) | 4.5 (1–11) | 4.3 (1–13) | 5.7 (1–45) |
| Lowest oxygen saturation (percent)d, mean (range) | 86.2 (77–93) | 83.0 (71–87) | 89.1 (75–98) | 89.0 (40–97) |
| Supplemental oxygen during hospitalization, n (%) | 46 (92.0) | 32 (100) | 14 (70.0) | 50 (72.5) |
| RSV subtypee | ||||
| RSV A | 30 | 24 | 15 | 48 |
| RSV B | 5 | 1 | 2 | 12 |
For age group restricted variables, percentages calculated out of total RSV-associated hospitalized children by age group.
Underlying conditions included chronic pulmonary and/or airway, cardiac, gastrointestinal, kidney, endocrine, neurologic and/or neuromuscular, hematologic and/or oncologic, genetic and/or metabolic, or immunocompromised conditions.
Received Palivizumab during the months of September 2019 through May 2020.
Documented in the first 24 h of admission.
Subtyping not available on all samples.
Variables with missing data: other children < 5 (Chinle n = 1, Whiteriver n = 1, Anchorage n = 1, Yukon-Kuskokwim (YK) Delta n = 5); currently breastfed (Chinle n = 1, Whiteriver n = 2, Anchorage n = 1, YK Delta n = 4); smoker in home (Chinle n = 1, Anchorage n = 1, YK Delta n = 4); running water (Chinle n = 1, Anchorage n = 1, YK Delta n = 4); under-lying conditions or prematurity (YK Delta n = 1); length of stay (YK Delta n = 5); oxygen saturation (Whiteriver n = 1, Anchorage n = 1, YK Delta n = 4); supplemental oxygen (Chinle n = 4; Anchorage n = 4, YK Delta n = 13).